Hit to Lead Account of the Discovery of a New Class of Inhibitors of Pim Kinases and Crystallographic Studies Revealing an Unusual Kinase Binding Mode

被引:69
作者
Qian, Kevin [1 ]
Wang, Lian [1 ]
Cywin, Charles L. [1 ]
Farmer, Bennett T., II [1 ]
Hickey, Eugene [1 ]
Homon, Carol [1 ]
Jakes, Scott [1 ]
Kashem, Mohammed A. [1 ]
Lee, George [1 ]
Leonard, Scott [1 ]
Li, Jun [1 ]
Magboo, Ronald [1 ]
Mao, Wang [1 ]
Pack, Edward [1 ]
Peng, Charlene [1 ]
Prokopowicz, Anthony, III [1 ]
Welzel, Morgan [1 ]
Wolak, John [1 ]
Morwick, Tina [1 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06801 USA
关键词
NF-KAPPA-B; E-MU-MYC; C-MYC; PHOSPHORYLATES BAD; STRUCTURAL BASIS; TRANSGENIC MICE; CK2; INHIBITOR; CELL-SURVIVAL; CANCER CELLS; PRE-B;
D O I
10.1021/jm801242y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of inhibitors of Pim-2 kinase identified by high-throughput screening is described. Details of the hit validation and lead generation process and structure-activity relationship (SAR) studies are presented. Disclosure of an unconventional binding mode for 1, as revealed by X-ray crystallography using the highly homologous Pim-1 protein, is also presented, and observed binding features are shown to correlate with the Pim-2 SAR. While highly selective within the kinase family, the series shows similar potency for both Pim-1 and Pim-2, which was expected on the basis of homology, but unusual in light of reports in the literature documenting a bias for Pim-1. A rationale for these observations based on Pim-1 and Pim-2 K-M(ATP) values is suggested. Some interesting cross reactivity with casein kinase-2 was also identified, and structural features which may contribute to the association are discussed.
引用
收藏
页码:1814 / 1827
页数:14
相关论文
共 83 条
[1]   Joining the cell survival squad: an emerging role for protein kinase CK2 [J].
Ahmed, K ;
Gerber, DA ;
Cochet, C .
TRENDS IN CELL BIOLOGY, 2002, 12 (05) :226-230
[2]   Pim-1 kinase promotes inactivation of the pro-apoptotic bad protein by phosphorylating it on the Ser112 gatekeeper site [J].
Aho, TLT ;
Sandholm, J ;
Peltola, KJ ;
Mankonen, HP ;
Lilly, M ;
Koskinen, PJ .
FEBS LETTERS, 2004, 571 (1-3) :43-49
[3]   Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc [J].
Allen, JD ;
Verhoeven, E ;
Domen, J ;
vanderValk, M ;
Berns, A .
ONCOGENE, 1997, 15 (10) :1133-1141
[4]   The survival kinases Akt and Pim as potential pharmacological targets [J].
Amaravadi, R ;
Thompson, CB .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2618-2624
[5]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[6]   The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2 [J].
Battistutta, R ;
Sarno, S ;
De Moliner, E ;
Papinutto, E ;
Zanotti, G ;
Pinna, LA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (38) :29618-29622
[7]   The human Pim-2 proto-oncogene and its testicular expression [J].
Baytel, D ;
Shalom, S ;
Madgar, I ;
Weissenberg, R ;
Don, J .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1442 (2-3) :274-285
[8]   Ruthenium half-sandwich complexes as protein kinase inhibitors:: An N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety [J].
Bregman, Howard ;
Meggers, Eric .
ORGANIC LETTERS, 2006, 8 (24) :5465-5468
[9]   Chemical inhibitors of protein kinases [J].
Bridges, AJ .
CHEMICAL REVIEWS, 2001, 101 (08) :2541-2571
[10]  
BUIJSMAN R, 2004, CHEMOGENOMICS DRUG D, V22, P191